TVAX Biomedical, Inc. products

TVAX Biomedical is developing an exciting new approach to cancer treatment that offers the promise of improved clinical outcomes, low toxicity and the potential for fundamentally changing the way cancer is treated.

TVAX®’s lead candidate (TVI-Brain-1) is being evaluated for the treatment of brain cancer and targets glioblastomas. The drug candidate has received Fast Track Designation by the US Food and Drug Administration (FDA) to test TVI-Brain-1 in a Phase 2b clinical study for glioblastoma multiforme (GBM). The Fast Track Designation is supported by positive Phase 2 clinical data, as well as extensive preclinical and Phase 1 safety studies.

TVAX®’s second candidate (TVI-Kidney-1) is being evaluated for the treatment of kidney cancer and targets stage 4 renal cell carcinoma.